934 related articles for article (PubMed ID: 15818697)
1. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
2. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
[TBL] [Abstract][Full Text] [Related]
3. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
4. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
5. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
Smolen JS; Van Der Heijde DM; St Clair EW; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Schiff M; Baker D; Han C; Han J; Bala M;
Arthritis Rheum; 2006 Mar; 54(3):702-10. PubMed ID: 16508926
[TBL] [Abstract][Full Text] [Related]
6. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
St Clair EW; van der Heijde DM; Smolen JS; Maini RN; Bathon JM; Emery P; Keystone E; Schiff M; Kalden JR; Wang B; Dewoody K; Weiss R; Baker D;
Arthritis Rheum; 2004 Nov; 50(11):3432-43. PubMed ID: 15529377
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
8. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462
[TBL] [Abstract][Full Text] [Related]
9. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
[TBL] [Abstract][Full Text] [Related]
10. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW
Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
[TBL] [Abstract][Full Text] [Related]
11. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
12. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C
J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
[TBL] [Abstract][Full Text] [Related]
13. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
14. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
16. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
17. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.
Taylor PC; Steuer A; Gruber J; McClinton C; Cosgrove DO; Blomley MJ; Marsters PA; Wagner CL; Maini RN
Arthritis Rheum; 2006 Jan; 54(1):47-53. PubMed ID: 16385521
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
19. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
